Short Course Low Dose Oral Colchicine After ST Elevation Myocardial Infarction(STEMI)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: CHITHAMBARAM SETHURAMAN, MBBS
- Phone Number: 8251 03-9145
- Email: chithambaramsethuraman@gmail.com
Study Contact Backup
- Name: HAMAT HAMDI, MBBchBAO
- Phone Number: 8251 03-9145
- Email: hamathamdi@gmail.com
Study Locations
-
-
Wilayah Persekutuan
-
Kuala Lumpur, Wilayah Persekutuan, Malaysia, 56000
- Recruiting
- Nationa University of Malaysia
-
Contact:
- CHITHAMBARAM SETHURAMAN, MBBS
- Phone Number: 8251 03-9145
- Email: chithambaramsethuraman@gmail.com
-
Contact:
- HAMAT HAMDI, MBBchBAO
- Phone Number: 8251 03-9145
- Email: hamathamdi@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 18 years to 80 years old
- STEMI within 24 hours of admission to Pusat Perubatan UKM & undergoing revascularization therapy (percutaneous coronary intervention) during admission
STEMI is diagnosed when there is:
- ST elevation of ≥1 mm in 2 contiguous leads or
- a new onset LBBB in the resting ECG
- in a patient with ischaemic type chest pains of > 30 minutes and
- accompanied by a rise and fall in cardiac biomarkers (CPG MALAYSIA STEMI 2019, 4th Edition)
Exclusion Criteria:
- Pre-existing severe heart failure with left ventricular ejection fraction less than 35%
- Clinically unstable (Intubated or double inotropic support)
- Refuse or not suitable for cardiac revascularization therapy
- Anaemia induced Angina (Hb < 9 g/dL)
- Ongoing sepsis requiring antibiotic
- Ongoing diarrhea (Loose stool 3 times or more per day - stool consistency Bristol chart type 6 & 7)
- Active Covid-19 Infection (< 7 days for Category 1-3, < 10 days for category 4-5)
- Stroke within previous 3 months
- Coronary bypass surgery either within the previous 3 years or planned
- Active malignancy or treated malignancy within 7 years
- Active Inflammatory bowel disease on treatment
- Active Neuromuscular disease on treatment
- Chronic kidney disease (CKD stage 4 - eGFR < 30 mL/min/1.73 m2)
- Severe hepatic disease (ALT > 3X upper limit normal, Bilirubin > 2X upper limit normal)
- Active drug or alcohol abuse on therapy
- On long term or recent systemic glucocorticoid therapy within 3 months
- Pregnancy or breastfeeding
- Known sensitivity to colchicine or multivitamin tablet
- Pre-existing indication for colchicine therapy (Gout, Familial Mediterranean fever, etc)
- Patients on oral medications that may interact with colchicine (Clarithromycin, Ketoconazole, Voriconazole, Fluconazole, Itraconazole, Cyclosporine, Ritonavir)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Colchicine Post ST Elevation Myocardial Infarction (STEMI)
32 patients with STEMI are assigned for oral colchicine 0.6 mg once daily upon admission for 30 days
|
Anti-Inflammatory Effects
Other Names:
|
|
Placebo Comparator: Placebo (Pyridoxine) Post ST Elevation myocardial Infraction (STEMI)
Another 32 patients with STEMI are assigned for placebo (oral pyridoxine 10 mg) once daily upon admission for 30 days
|
Colchicine look alike placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anti-Inflammatory Effect of Colchicine
Time Frame: 3-7 days
|
Serum Troponin I change from arrival to discharge
|
3-7 days
|
|
Major Adverse Cardiac Events (MACE)
Time Frame: 3 months
|
Recurrent myocardial infarction, unstable angina needing hospital admission, cardiac death, unplanned repeated revascularization, cerebrovascular accident
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Trans thoracic Echo cardiogram parameters
Time Frame: 3 months
|
Left ventricular ejection fraction (biplane mode) measured in %, left ventricular volume measured in milliliters, left atrial volume measured in milliliters, E/A ratio, E/e ' ratio
|
3 months
|
|
Safety of colchicine
Time Frame: 1 month
|
Number of Participants with medication side effects
|
1 month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: HAMAT HAMDI, MBBchBAO, Head of Cardiology Unit
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Myocardial Infarction
- Infarction
- ST Elevation Myocardial Infarction
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Micronutrients
- Vitamins
- Vitamin B Complex
- Gout Suppressants
- Colchicine
- Vitamin B 6
- Pyridoxal
- Pyridoxine
Other Study ID Numbers
Other Study ID Numbers
- FF-2023-191
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.